Scholar Rock Holding Corp

Scholar Rock Holding Corporation has filed a prospectus supplement to offer and sell up to $200,000,000 of its common stock through an at-the-market (ATM) offering program with Jefferies LLC. This new offering replaces a prior ATM program, which has been terminated. The company previously raised approximately $257.7 million in net proceeds from shares sold under the earlier ATM program.

Scholar Rock Holding Corp. announced the resubmission of its Biologics License Application (BLA) for apitegromab to the FDA in March 2026, with a PDUFA action date of September 30, 2026. This follows a Complete Response Letter in September 2025 related to third-party manufacturing facilities. For the first six months of 2026, the company reported a net loss of $(215.4) million, an increase from the prior year, with total operating expenses rising to $210.9 million. The company strengthened its financial position through financing activities, including $160.8 million from an at-the-market offering, ending the period with $492.1 million in cash, cash equivalents, and marketable securities.

Scholar Rock Holding Corporation reported a net loss of $109.9 million for the second quarter of 2026, with a net loss per common share of $0.84. The company maintained a strong financial position with $492.1 million in cash, cash equivalents, and marketable securities, including $62.8 million from its ATM program. Key business highlights include the continued advancement of the apitegromab Biologics License Application (BLA) review by the FDA, with a PDUFA date of September 30, 2026, and the initiation of a Phase 2 study for apitegromab in FSHD.

Scholar Rock Holding Corp. reported a net loss of $105.5 million for the first quarter of 2026, an increase from $74.7 million in Q1 2025, primarily due to higher operating expenses. The company significantly bolstered its cash position to $430.5 million, driven by $98.0 million from common share sales and $196.7 million from a new debt facility. The Biologics License Application (BLA) for apitegromab was resubmitted in March 2026, with a Prescription Drug User Fee Act (PDUFA) action date set for September 30, 2026. Scholar Rock anticipates its current cash resources will fund operations for at least one year.

Scholar Rock announced its Q1 2026 financial results and significant business updates. The FDA accepted the Biologics License Application (BLA) for apitegromab for spinal muscular atrophy (SMA), setting a PDUFA action date of September 30, 2026. The company reported a net loss of $105.5 million for the quarter, with cash, cash equivalents, and marketable securities totaling $479.9 million as of March 31, 2026. Preparations for a U.S. commercial launch are underway, with European regulatory review also progressing.